<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864565</url>
  </required_header>
  <id_info>
    <org_study_id>02348</org_study_id>
    <nct_id>NCT00864565</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Fentanyl 25 μg/h Transdermal System</brief_title>
  <official_title>Randomized, 2-way Crossover, Bioequivalence Study of Fentanyl 25 μg/h Transdermal System and Duragesic 25 μg/h Transdermal System Administrated as 1 x 25 μg/h Single Application in the Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the rate and extent of absorption of fentanyl 25 μg/h transdermal system (test)&#xD;
      and Duragesic (reference) administrated as 1 x 25 μg/h single transdermal system application.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design.&#xD;
&#xD;
      Official Title: Randomized, 2-way crossover, bioequivalence study of Fentanyl 25 μg/h&#xD;
      transdermal system and Duragesic 25 μg/h transdermal system administrated as 1 x 25 μg/h&#xD;
      single application in the healthy subjects&#xD;
&#xD;
      Further study details as provided by Actavis Elizabeth LLC:&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Rate and Extend of Absorption&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>132 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fentanyl 25 μg/h transdermal system, single application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duragesic 25 μg/h transdermal system single application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl 25 μg/h transdermal system, single application</intervention_name>
    <description>A: Experimental Subjects received Corium International, Inc formulated products</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Fentanyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duragesic 25 μg/h transdermal system single application</intervention_name>
    <description>B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Fentanyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will be females and/or males, smokers and/or non-smokers, between 18 and 55&#xD;
             years of age.&#xD;
&#xD;
          -  Subject capable of consent.&#xD;
&#xD;
          -  Female subjects will be post-menopausal or surgically sterilized.&#xD;
&#xD;
               1. Post-menopausal status is defined as absence of menses for the past 12 months or&#xD;
                  hysterectomy with bilateral oophorectomy at least 6 months ago.&#xD;
&#xD;
               2. Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal&#xD;
                  ligation at least 6 months ago.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks of the administration of study&#xD;
             medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Positive urine drug screen at screening.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C or HlV at screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 100 or over 140 mmHg, or diastolic blood pressure lower than 60 or&#xD;
             over 90 mmHg; or heart rate less than 60 or over 100 bpm) at screening.&#xD;
&#xD;
          -  Subjects with BMI &gt;30.0.&#xD;
&#xD;
          -  History of significant alcohol abuse within six months of the screening visit or any&#xD;
             indication of the regular use of more than fourteen units of alcohol per week (1 Unit&#xD;
             ≈ 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).&#xD;
&#xD;
          -  History of abuse or dependency or use of illegal drugs: use of soft drugs (such as&#xD;
             marijuana) within 3 months of the screening visit or hard drugs (such as cocaine,&#xD;
             phencyclidine (PCP) and crack) within I year of the screening visit.&#xD;
&#xD;
          -  History of allergic reactions to fentanyl, naloxone or adhesives.&#xD;
&#xD;
          -  History of allergic reactions to heparin.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin;&#xD;
             examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin,&#xD;
             ketoconazole, MAO .inhibitors, neuroleptics, verapamil, quinidine) within 30 days&#xD;
             prior to administration -of the study medication.&#xD;
&#xD;
          -  Use of an investigational drug or participation in an investigational study within 30&#xD;
             days prior to administration of the study medication.&#xD;
&#xD;
          -  History or presence of any clinically significant liver or kidney disease or other&#xD;
             conditions known to interfere with the absorption, distribution, metabolism or&#xD;
             excretion of the drug.&#xD;
&#xD;
          -  Any history or presence of clinically significant neurological. endocrinal,&#xD;
             cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products (including natural food supplements, vitamins,&#xD;
             garlic as supplement) within 7 days prior to administration of study medication,&#xD;
             except for topical products without systemic absorption.&#xD;
&#xD;
          -  Smoking more than 25 cigarettes per day.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             medical subinvestigator, contraindicates the subject's participation in this study.&#xD;
&#xD;
          -  Subjects who have had a depot injection or an implant of any drug 3 months prior to&#xD;
             administration of study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to&#xD;
             administration of the study medication as follows:&#xD;
&#xD;
             1.less than 300 mL of whole blood within 30 days or 2.300 mL to 500 mL of whole blood&#xD;
             within 45 days or 3.more than 500 mL of whole blood within 56 days .&#xD;
&#xD;
          -  Subjects who have consumed food or beverages containing grapefruit (e.g. fresh,&#xD;
             canned, or frozen) within 7 days prior to administration of the study medication.&#xD;
&#xD;
          -  Subjects with a history or presence of asthma. chronic obstructive pulmonary disease&#xD;
             or other pulmonary condition that may predispose to hypoventilation.&#xD;
&#xD;
          -  Subjects with a history or presence of bradyarrythmias.&#xD;
&#xD;
        Additional criteria for females only:&#xD;
&#xD;
          -  Breast-feeding subjects.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening (performed on all females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc</name>
      <address>
        <city>Quebec</city>
        <zip>G1V2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Fentanyl</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

